Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced results from a clinical study have found that its gas-sensing capsule can be used to provide insights into localization of colonic fermentation.
Atmo Biosciences, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function, has appointed a Medical Advisory Board (MAB), comprising world-renowned gastroenterologists.
Atmo Biosciences Limited, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gut health and microbiome function, has made three key appointments, further building capability at the executive and Board levels:Atmo Biosciences, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function, has appointed a Medical Advisory Board (MAB), comprising world-renowned gastroenterologists.
Atmo Biosciences, a clinical stage gut health company developing the World’s first ingestible gas-sensing capsule, is pleased to announce publication of a clinical study supporting the Atmo Gas Capsule’s ability to determine its location in the gastrointestinal tract. The study demonstrates strong agreement between data from Atmo’s Gas Capsule and a validated, FDA-cleared Wireless Motility Capsule (WMC), in determining transit metrics in healthy subjects. Based on these encouraging data, Atmo intends to conduct a clinical trial in patients with gastrointestinal motility disorders.
Atmo Biosciences, a clinical stage gut health company, is pleased to announce that the US Patent and Trademark Office (USPTO) has granted the patent for Atmo’s ingestible gas sensor capsule. The Atmo Gas Capsule is the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function.
